Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
Assignee
Regeneron Pharmaceuticals, Inc.
Inventors
David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman
Abstract
CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
CPC Classifications
Filing Date
2024-01-23
Application No.
18420588
Claims
35